We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Levels of Circulating Cell-Free DNA Predict Risk of Developing Dementia

By LabMedica International staff writers
Posted on 12 Oct 2022

A test that measured the amount of cell-free DNA fragments in the blood was able to identify individuals at higher risk of developing dementia, worsening cognition. More...

and frailty.

Altered cellular equilibrium, seen in cognitive decline and frailty, leads to cell death and turnover, releasing circulating cell-free DNA (ccf-DNA). In a recently published study, investigators at Johns Hopkins University (Baltimore, MD, USA) determined whether serum genomic cell-free DNA (ccf-gDNA) was associated with physical and cognitive decline in older adults.

For this study, the investigators used digital PCR to analyze blood samples from 631 individuals with an average age of 79 years who showed no cognitive impairment when the study began. An array of cognitive and physical traits, risk of dementia, global cognition, and frailty at or nearest the time of blood draw were compared to ccf-DNA levels, with adjustment for age, sex, race, and education. The data gathering period lasted for eight years.

Results across the group showed that higher ccf-gDNA levels were associated with lower global cognition score and slower gait speed at the evaluation nearest to blood draw. Furthermore, higher ccf-gDNA levels were associated with increased odds of incident dementia. Individually, higher levels of ccf-gDNA were associated with steeper general cognitive decline and worsening frailty over the eight years of follow up.

“These ccf-gDNA fragments may trigger long-term chronic inflammatory reactions that have previously been linked to the premature destruction and aging of tissues and organs, including the brain,” said senior author Dr. Peter Abadir, associate professor of geriatric medicine and gerontology at Johns Hopkins University. “The body sees these ccf-gDNA fragments as something that needs to be removed, therefore the body’s immune system is running at a higher rate than it should. Such immune system overdrive may be a factor in identifying the onset of dementia.”

Results of the study were published in the October 11, 2022, issue of the Journal of Alzheimer’s Disease.

Related Links:
Johns Hopkins University 


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.